NCT02868996View on ClinicalTrials.gov

An Open Label, Phase 1b, Ascending Dose Study of DM199

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Stroke
Interventions
DRUG

Recombinant human tissue kallikrein

Intravenous DM199

Trial Locations (1)

Unknown

Linear Clinical Research, Perth

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

DiaMedica Therapeutics Inc

INDUSTRY

NCT02868996 - An Open Label, Phase 1b, Ascending Dose Study of DM199 | Biotech Hunter | Biotech Hunter